intro
We identify, protect, develop and commercialise intellectual property (IP) arising from research at the Crick.
Get in touch with the Innovation and Business team to find out how you can work with us.
Our approach
Our goal is to maximise the impact of the Crick’s scientific innovations by ensuring that intellectual property is appropriately identified and managed in a way that also allows for timely dissemination and publication of research findings.
Appropriate protection of intellectual property is necessary to secure the commercial investment required to develop novel products and technologies from Crick science. This also allows the Crick to benefit from financial returns generated from commercialisation of intellectual property.
We achieve this by:
- obtaining IP protection to enable future commercial development
- helping to secure translational funding to strengthen and add value to IP
- aligning IP development strategies with future partners (e.g. potential industrial licensees, investors and collaborators)
- enabling IP commercialisation, usually via collaborations, licensing and the creation of spin-out companies supported by venture funding
Selected IP opportunities
We have a range of active IP licensing and collaborative opportunities, including:
- antibody-drug conjugate (ADC) for treatment of inflammatory bowel disease - project lead, James Lee
- automated 3D organoid culture and analysis to accelerate discovery - project lead, Andrea Serio
- RET receptor agonists to enhance survival of neurons in Parkinson’s Disease - project lead, Neil McDonald
- drug screening models for fatty acid / amino acid dysregulation in metabolic disease - project lead, Alex Gould
- thymic organoids for T- therapy - project lead, Paola Bonfanti
- disease model for discovery and validation of muscular dystrophy therapies - project lead, Saverio Tedesco
- CD74 as a biomarker for responsiveness to cancer immunotherapy - project lead, Francesca Ciccarelli
- biomarker and treatment strategy for early relapse follicular lymphoma - project lead, Dinis Calado
Contact us for details of our current IP opportunities.
Email usSpin-out companies
Spin-out companies
Assembling a team of dedicated scientists and experts can attract the significant investment needed to develop a technology.
Explore our spin-outs